<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article">
	<front>
		<journal-meta>
			<journal-title-group>
				<journal-title>Current issues in pharmacy and medicine: science and practice</journal-title>
			</journal-title-group>
			<issn pub-type="epub">2409-2932</issn>
			<issn pub-type="ppub">2306-8094</issn>
			<publisher>
				<publisher-name>Zaporizhzhia State Medical and Pharmaceutical University</publisher-name>
			</publisher>
		</journal-meta>
		<article-meta>
			<article-id pub-id-type="doi">10.14739/2409-2932.2025.3.338591</article-id>
			<title-group>
				<article-title>Comorbidity among patients with community-acquired pneumonia combined with coronavirus disease</article-title>
			</title-group>
			<contrib-group>
				<contrib contrib-type="author">
					<name>
						<given-names>O. S.</given-names>
						<surname>Kulbachuk</surname>
					</name>
					<xref ref-type="aff" rid="aff1"/>
					<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0646-6701</contrib-id>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<given-names>Ye. V.</given-names>
						<surname>Sid</surname>
					</name>
					<xref ref-type="aff" rid="aff1"/>
					<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9198-9640</contrib-id>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<given-names>O. V.</given-names>
						<surname>Soloviov</surname>
					</name>
					<xref ref-type="aff" rid="aff1"/>
					<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2916-6106</contrib-id>
				</contrib>
				<contrib contrib-type="author">
					<name>
						<given-names>A. V.</given-names>
						<surname>Piskun</surname>
					</name>
					<xref ref-type="aff" rid="aff1"/>
					<contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6431-9617</contrib-id>
				</contrib>
			</contrib-group>
			<aff id="aff1">Zaporizhzhia State Medical and Pharmaceutical University</aff>
			<author-notes><fn><p>Oleksandr Soloviov <email>soloviov.ov@gmail.com</email></p></fn></author-notes>
			<pub-date pub-type="epub">
				<day>24</day>
				<month>11</month>
				<year>2025</year>
			</pub-date>
			<volume>18</volume>
			<issue>3</issue>
			<fpage>356</fpage>
			<lpage>362</lpage>
			<language>uk</language>
			<abstract>
				<p>The aim of the work is to analyze and evaluate data from professional literature sources regarding comorbid conditions among patients with community-acquired pneumonia combined with coronavirus disease.</p>
				<p>Materials and methods. Using primary sources from the scientometric databases Scopus, Web of Science, PubMed, a retrospective analysis of literature data on the issue of comorbidity in patients with community-acquired pneumonia combined with coronavirus disease for 2020–2025 was conducted.</p>
				<p>Results. This article examines the impact of comorbid cardiovascular diseases during COVID-19 and the mortality rate. Literature analysis shows that the presence of cardiovascular diseases increases the chances of developing a severe course of COVID-19 by three times. Elderly people and patients with hypertension and diabetes have the worst prognosis for COVID-19. Studies indicate increased morbidity and mortality among patients with diabetes, as well as the relationship between glucose levels and disease severity. The works of various authors emphasize the importance of early diagnosis and hospitalization, as well as the need for an integrated approach to treatment, including the cooperation of cardiologists and pulmonologists. It is also noted that patients with chronic diseases, such as bronchial asthma and chronic obstructive pulmonary disease, are at higher risk of severe COVID-19. The article also discusses the mechanisms of inflammatory damage to the heart that are detected during the disease and their relationship with prognosis.</p>
				<p>Conclusions. Timely diagnosis and treatment of comorbid conditions are need to reduce the risk of complications in patients with COVID-19. The article emphasizes the important role of family doctors in monitoring and managing chronic diseases, which can significantly alleviate the course of COVID-19. The prospects for further research are to identify markers of the immunoinflammatory response to predict the course in patients with community-acquired pneumonia associated with coronavirus infection with comorbid pathology.</p>
			</abstract>
			<kwd-group kwd-group-type="author">
				<kwd>community-acquired pneumonia</kwd>
				<kwd>inflammatory markers</kwd>
				<kwd>comorbidity</kwd>
				<kwd>thrombosis</kwd>
				<kwd>coronavirus disease</kwd>
				<kwd>SARS-CoV-2</kwd>
				<kwd>COVID-19</kwd>
			</kwd-group>
			<self-uri content_type="abstract">https://pharmed.zsmu.edu.ua/article/view/338591</self-uri>
			<self-uri content_type="pdf">https://pharmed.zsmu.edu.ua/article/download/338591/331768</self-uri>
		</article-meta>
	</front>
</article>
